November 2024 Newsletter
Imagine if your scientific data provided the full picture - so you could make faster, actionable and more predictive decisions. Watch the short video below to learn how we are removing the guesswork involved with oncology drug discovery and development ??
Throughout November, we've supported Lung Cancer Awareness Month. ??? This month's edition focuses on highlighting impactful research in preclinical drug discovery.
Lung cancer is the leading cause of cancer-related deaths worldwide, so choosing the right preclinical models is vital for successful oncology drug discovery. By utilizing our free cancer model databases, researchers gain a significant advantage in their preclinical oncology studies with time and cost savings.
Access diverse and well-characterized tumor models, along with extensive profiling and pharmacologic data, to make confident and well-informed decisions during oncology drug discovery.
Read our scientific poster on a panel of KRAS G12C inhibitor-resistant tumor models generated to evaluate clinical strategies to overcome resistance to KRAS-targeted therapies.
This case study?evaluated a new preclinical model aimed at identifying strategies and new therapeutics to overcome C797S mediated drug resistance.
Discover the generation of drug resistant HCC827 NSCLC CDX models for understanding mechanisms of resistance and testing new targeted treatments.
Our lung cancer patient-derived xenograft models offer the most translational preclinical models for efficacy screening in cancer drug development.
Download our research poster to see the results of integrating spatial transcriptomics and bulk RNA-Seq as a basis of understanding gene expression profiles in NSCLC.
Biomarker analysis is revolutionizing drug development and precision medicine by enabling personalized treatment approaches. Read our latest blog post for more insights.
? 2024 Crown Bioscience
Crown Bioscience, Inc. 16550 West Bernardo Drive, Building 5, Suite 525, San Diego, CA 92127, United States